We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
WST Stock Builds on GLP-1 Growth, Annex 1 and Margins in Focus
Read MoreHide Full Article
Key Takeaways
WST is seeing strong growth from GLP-1-related high-value components and auto-injector demand.
WST's Annex 1 projects are driving a favorable mix shift toward higher-margin pharma offerings.
Margin pressure stems from WST's lower-margin product growth, pricing headwinds and $20-$25M in new tariffs.
West Pharmaceutical Services, Inc. (WST - Free Report) is well-positioned for growth, backed by the robust GLP-1 related demand and its expansion plans. However, pricing headwinds and tariff risks are concerning.
Shares of this Zacks Rank #2 (Buy) company have lost 32.5% so far this year compared with the industry's 0.6% decline. The S&P 500 Index has increased 2.8% in the same time frame.
West Pharmaceutical, with a market capitalization of $16 billion, is a leading global manufacturer, engaged in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Its earnings are anticipated to improve 6.5% over the next five years. The company delivered a trailing four-quarter average earnings surprise of 7.81%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Key Catalysts
Strength in GLP-1 Related Demand: WST’s high-value product (HVP) components tied to GLP-1 therapies (notably used in obesity and diabetes treatments) are performing well. These accounted for about 7% of total revenues in the first quarter and continue to grow. Additionally, the GLP-1 auto-injector business within the Contract Manufacturing segment is ramping up, helping offset revenue loss from CGM contract exits. The company has also repurposed COVID-era infrastructure to support this GLP-1 growth, enhancing capital efficiency.
Expansion Opportunities: Annex 1-related projects (focused on sterile manufacturing compliance in Europe) are contributing meaningfully, with 340 active customer projects versus 280 last quarter. This initiative drives a favorable mix shift toward premium-margin HVP offerings, particularly in standard and generic pharma categories, which could materially impact growth and margins in the forthcoming quarters, even if its current revenue contribution is modest.
Operational Efficiency and Margin Management:Despite pricing pressure and a temporary supply constraint at one facility, WST is maintaining margins through improved operational efficiency, restructuring actions and SG&A control. Automation of SmartDose production (expected late 2025/early 2026) is a long-term lever to improve margins in delivery devices. WST has also reaffirmed its capital allocation toward margin-accretive investments and shareholder returns, further supporting EPS upside.
Factors Hurting the Stock
West Pharmaceutical Services is facing a combination of margin pressure, pricing headwinds, and tariff-related risks that could weigh on its performance through the remainder of 2025.
A significant contributor to margin pressure stems from a shift in product mix — specifically growth in lower-margin delivery devices like SmartDose and contract manufacturing projects, which are currently diluting the profitability achieved from high-value components such as FluroTec. While initiatives like automation are underway to improve cost efficiency, their benefits may not materialize until late 2025 or early 2026.
Adding to this, WST has flagged softer-than-expected pricing realization for the full year. Although price increases contributed meaningfully to first-quarter revenue growth, management now anticipates lighter pricing contributions going forward, reflecting both customer dynamics and competitive pressures.
On top of these internal challenges, the company faces external headwinds from evolving geopolitical risks. Newly imposed tariffs are projected to create a $20-$25 million cost burden over the next three quarters, with uncertainty around potential retaliatory actions. While WST is actively pursuing mitigation strategies, including possible cost pass-throughs, these are not yet reflected in its updated guidance. These factors, in unison, cause earnings volatility and constrain the company’s ability to fully leverage demand momentum.
The company has been witnessing a stable estimate movement for 2025. In the past 30 days, the Zacks Consensus Estimate for earnings has remained unchanged at $6.28 per share, implying a decline of 7% from the prior-year level. The consensus mark for revenues is pegged at $2.97 billion, indicating a 2.5% increase from the 2024 level.
Key Picks
Some other top-ranked stocks from the same medical industry are Align Technology (ALGN - Free Report) , Cardinal Health (CAH - Free Report) and McKesson (MCK - Free Report) .
ALGN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 3.4%. ALGN’s shares have lost 10.3% so far this year.
Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated growth rate of 10.9% for the next five years.
CAH’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 10.3%. Cardinal Health’s shares have risen 38.4% year to date.
McKesson, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 13.5% for the next five years.
MCK’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 3.93%. McKesson’s shares have gained 26% so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
WST Stock Builds on GLP-1 Growth, Annex 1 and Margins in Focus
Key Takeaways
West Pharmaceutical Services, Inc. (WST - Free Report) is well-positioned for growth, backed by the robust GLP-1 related demand and its expansion plans. However, pricing headwinds and tariff risks are concerning.
Shares of this Zacks Rank #2 (Buy) company have lost 32.5% so far this year compared with the industry's 0.6% decline. The S&P 500 Index has increased 2.8% in the same time frame.
West Pharmaceutical, with a market capitalization of $16 billion, is a leading global manufacturer, engaged in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Its earnings are anticipated to improve 6.5% over the next five years. The company delivered a trailing four-quarter average earnings surprise of 7.81%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Key Catalysts
Strength in GLP-1 Related Demand: WST’s high-value product (HVP) components tied to GLP-1 therapies (notably used in obesity and diabetes treatments) are performing well. These accounted for about 7% of total revenues in the first quarter and continue to grow. Additionally, the GLP-1 auto-injector business within the Contract Manufacturing segment is ramping up, helping offset revenue loss from CGM contract exits. The company has also repurposed COVID-era infrastructure to support this GLP-1 growth, enhancing capital efficiency.
Expansion Opportunities: Annex 1-related projects (focused on sterile manufacturing compliance in Europe) are contributing meaningfully, with 340 active customer projects versus 280 last quarter. This initiative drives a favorable mix shift toward premium-margin HVP offerings, particularly in standard and generic pharma categories, which could materially impact growth and margins in the forthcoming quarters, even if its current revenue contribution is modest.
Operational Efficiency and Margin Management:Despite pricing pressure and a temporary supply constraint at one facility, WST is maintaining margins through improved operational efficiency, restructuring actions and SG&A control. Automation of SmartDose production (expected late 2025/early 2026) is a long-term lever to improve margins in delivery devices. WST has also reaffirmed its capital allocation toward margin-accretive investments and shareholder returns, further supporting EPS upside.
Factors Hurting the Stock
West Pharmaceutical Services is facing a combination of margin pressure, pricing headwinds, and tariff-related risks that could weigh on its performance through the remainder of 2025.
A significant contributor to margin pressure stems from a shift in product mix — specifically growth in lower-margin delivery devices like SmartDose and contract manufacturing projects, which are currently diluting the profitability achieved from high-value components such as FluroTec. While initiatives like automation are underway to improve cost efficiency, their benefits may not materialize until late 2025 or early 2026.
Adding to this, WST has flagged softer-than-expected pricing realization for the full year. Although price increases contributed meaningfully to first-quarter revenue growth, management now anticipates lighter pricing contributions going forward, reflecting both customer dynamics and competitive pressures.
On top of these internal challenges, the company faces external headwinds from evolving geopolitical risks. Newly imposed tariffs are projected to create a $20-$25 million cost burden over the next three quarters, with uncertainty around potential retaliatory actions. While WST is actively pursuing mitigation strategies, including possible cost pass-throughs, these are not yet reflected in its updated guidance. These factors, in unison, cause earnings volatility and constrain the company’s ability to fully leverage demand momentum.
West Pharmaceutical Services, Inc. Price
West Pharmaceutical Services, Inc. price | West Pharmaceutical Services, Inc. Quote
Estimates Trend
The company has been witnessing a stable estimate movement for 2025. In the past 30 days, the Zacks Consensus Estimate for earnings has remained unchanged at $6.28 per share, implying a decline of 7% from the prior-year level. The consensus mark for revenues is pegged at $2.97 billion, indicating a 2.5% increase from the 2024 level.
Key Picks
Some other top-ranked stocks from the same medical industry are Align Technology (ALGN - Free Report) , Cardinal Health (CAH - Free Report) and McKesson (MCK - Free Report) .
Align Technology, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 11.2% for the next five years. You can see the complete list of today’s Zacks #1 Rank stocks here.
ALGN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 3.4%. ALGN’s shares have lost 10.3% so far this year.
Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated growth rate of 10.9% for the next five years.
CAH’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 10.3%. Cardinal Health’s shares have risen 38.4% year to date.
McKesson, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 13.5% for the next five years.
MCK’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 3.93%. McKesson’s shares have gained 26% so far this year.